Drug Profile
Research programme: anticancer therapeutics - Schering
Alternative Names: 4-thio-FAC; Anticancer therapeutics research programme - ScheringLatest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Class Deoxyribonucleosides
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Apr 2004 4-thio-FAC is available for co-developing worldwide (http://www.schering.de/eng/)
- 08 Apr 2004 Preclinical trials in Cancer in Germany (unspecified route)
- 08 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)